XML 17 R7.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 9 Months Ended
Mar. 31, 2019
Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income attributable to Myriad Genetics, Inc. stockholders $ 8.8 $ 118.9 [1]
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 54.6 39.3 [1]
Non-cash interest expense 0.3 0.1 [1]
Loss (gain) on disposition of assets (0.9) 0.1 [1]
Share-based compensation expense 24.7 20.0 [1]
Deferred income taxes 3.0 (24.9) [1]
Unrecognized tax benefits (7.3) 2.7 [1]
Change in fair value of contingent consideration (1.4) (61.3) [1]
Payment of contingent consideration (1.5) (20.8) [1]
Changes in assets and liabilities:    
Prepaid expenses 2.0 2.7 [1]
Trade accounts receivable (27.0) (14.4) [1]
Other receivables (0.4) 4.1 [1]
Inventory 7.4 8.9 [1]
Prepaid taxes (3.0) (2.7) [1]
Accounts payable (8.1) (2.0) [1]
Accrued liabilities 1.4 (2.6) [1]
Deferred revenue (0.4) (0.1) [1]
Net cash provided by operating activities 52.2 68.0 [1]
CASH FLOWS FROM INVESTING ACTIVITIES    
Capital expenditures (7.2) (6.6) [1]
Acquisitions, net of cash acquired (278.5)  
Purchases of marketable investment securities (57.0) (79.4) [1]
Proceeds from maturities and sales of marketable investment securities 51.8 65.5 [1]
Net cash used in investing activities (290.9) (20.5) [1]
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds from common stock issued under share-based compensation plans 6.5 18.2 [1]
Net proceeds from revolving credit facility 340.0 53.0 [1]
Repayment of revolving credit facility (85.0) (83.0) [1]
Fees associated with refinancing of revolving credit facility (1.4)  
Payment of contingent consideration recorded in purchase accounting [1]   (42.4)
Repurchase and retirement of common stock (50.0)  
Proceeds from non-controlling interest [1]   0.5
Net cash provided by (used in) financing activities 210.1 (53.7) [1]
Effect of foreign exchange rates on cash and cash equivalents 2.6 1.2 [1]
Net decrease in cash and cash equivalents (26.0) (5.0) [1]
Cash and cash equivalents at beginning of the period [1] 110.9 102.4
Cash and cash equivalents at end of the period $ 84.9 $ 97.4 [1]
[1] Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). See Note 1 to the financial statements contained in Part I, Item 1 of this report for additional information.